Patrys Ltd has released a press release.
PAT-DX1 is synergistic with PARP inhibitor
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- Collaboration with WEHI
- Appendix 4C - Quarterly - 30 September 2017
- PAB and Garvan Institute of Medical Research Awarded Grant
- US Patent Granted for Preclinical Candidate PAT-LM1
- PAT-DX1 Conjugated to Nanoparticles, Targets Tumors
Later from Patrys
- Entitlement Offer Booklet
- PAT-DX1-NP Localizes to Lymph Node Metastases
- Publication and Patent Filing for Humanized Version of 3E10
- Appendix 4C - Quarterly - 31 December 2017
- Appendix 4D - Half Year Accounts - 31 December 2017
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys